Skip to main
OFIX

Orthofix International (OFIX) Stock Forecast & Price Target

Orthofix International (OFIX) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Orthofix Medical Inc. demonstrated robust financial performance, with the Global Spine segment achieving a notable 10% revenue growth, driven by strong market share capture and significant growth in several key product categories. Additionally, the US spinal fixation sector reported a 5% revenue increase, further indicating the company's competitive positioning within the orthopedic market. The company's longer-term outlook is bolstered by the expectation of continued growth in the bone growth therapy (BGT) business, projected to outpace market growth rates of 2% to 3% through strategic cross-selling initiatives.

Bears say

Orthofix Medical Inc. has illustrated a negative outlook due to disappointing long-term guidance, pushing its adjusted EBITDA margin target to 2028 and revealing lower-than-expected financial performance for 2026 and 2027. Despite achieving a revenue of $219.9 million, which exceeded estimates, the company's spinal implant and biologics revenue fell short, indicating potential weaknesses in key product areas such as 7D Flash Navigation and biologics. Additionally, the company's GAAP SG&A expenses were significantly higher than anticipated, further exacerbating concerns regarding operational efficiency and profitability.

Orthofix International (OFIX) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Orthofix International and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Orthofix International (OFIX) Forecast

Analysts have given Orthofix International (OFIX) a Buy based on their latest research and market trends.

According to 4 analysts, Orthofix International (OFIX) has a Buy consensus rating as of Apr 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Orthofix International (OFIX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.